Join the experts in this session to learn about highly relevant, clinical hot topic issues for hepatitis B management in 2025. Topics include: quantitative HBsAg testing in clinical practice; HCC risk calculators; noninvasive testing for hepatic fibrosis; and metabolic dysfunction-associated steatotic liver disease in patients with HBV infection.
Quantitative Hepatitis B Surface Antigen Testing in Clinical Practice: Different Sources of Production, Prognostic Value, and Using Results to Guide Initiation of Treatment
Scott K. Fung, MD, FRCPC, FAASLD
, Moderator
Hepatitis
8:15 AM
- 8:30 AM
Nov
08
2025
Washington, D.C.
Noninvasive Tests to Assess Hepatic Fibrosis in Chronic Hepatitis B: Elastography, FIB-4, APRI, and ELF Score
Richard Sterling, MD, MSc, FAASLD
, Presenter
Hepatitis
8:30 AM
- 8:45 AM
Nov
08
2025
Washington, D.C.
Hepatocellular Carcinoma Calculators in Clinical Practice: REACH-B, mPAGE, GALAD, and ALBI Scores, and Special Populations
Terry Cheuk-Fung Yip, PhD
, Presenter
Hepatitis
8:45 AM
- 9:00 AM
Nov
08
2025
Washington, D.C.
Metabolic Dysfunction-Associated Steatotic Liver Disease and Hepatitis B Infection (Met-HBV): Epidemiology, Serologic Profile, and Histology Studies
Helena Cortez-Pinto, MD, PhD, FAASLD
, Presenter
Hepatitis
9:00 AM
- 9:15 AM
Nov
08
2025
Washington, D.C.
Metabolic Dysfunction-Associated Steatotic Liver Disease and Hepatitis B: Clinical Management and Outcomes—Cirrhosis, Hepatocellular Carcinoma Risk, Cardiovascular Risk, and Seroclearance Rates
Mandana Khalili, MD
, Presenter
Hepatitis
Objectives
Explain the clinical utility of quantitative HBsAg testing in the management of chronic hepatitis B infection.
Describe how to estimate HCC risk in patients with chronic hepatitis B infection based on risk calculators.
Review the assessment of hepatic fibrosis using noninvasive testing in patients with chronic hepatitis B infection.
Summarize the impact of MASLD/ MASH in patients with chronic hepatitis B infection in terms of clinical outcomes.